<DOC>
	<DOCNO>NCT00549328</DOCNO>
	<brief_summary>This study design evaluate efficacy safety monotherapy pazopanib ( small molecule tyrosine kinase inhibitor VEGFR-1 , VEGFR-2 , VEGFR-3 , PDGF , c-kit ) subject advance ( Stage IIIB IV ) non-small cell lung cancer .</brief_summary>
	<brief_title>Monotherapy Pazopanib Subjects With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Study 109609 single-arm , non-randomized , single-stage Phase II study pazopanib subject Stage IIIB IV non-small cell lung cancer progress one two prior regimen systemic therapy . The study conduct limited number institution US . A total 40 evaluable subject enrol treat . Pazopanib give dose 800mg ( determine previous Phase I study ) orally per day . Subjects may continue receive study drug two year unless experience disease progression withdraw treatment reason , unless Sponsor terminate study . A rollover study may available subject exhibit clinical benefit ( stable disease well ) . Evaluable subject assess response primary endpoint .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Signed consent Histologically cytologically confirm diagnosis Stage IIIB IV nonsmall cell lung cancer . Failed two prior chemotherapy regimens Stage IIIB IV nonsmall cell lung cancer , include platinumcontaining regimen . Brain metastasis permit subject treat surgery and/or radiation therapy 4 week prior date first dose stable least one week steroid . 18 year age old . Eastern Cooperative Oncology Group performance status least 2 . Measurable disease accord RECIST . Adequate organ system function . Females may eligible enroll nonchildbearing potential ( surgically sterile postmenopausal ) use appropriate contraception method . Prior malignancy unless diseasefree least 3 year , completely resect nonmelanomatous skin cancer successfully treat situ carcinoma . History clinical evidence central nervous system metastasis leptomeningeal carcinomatosis , except subject previouslytreated CNS metastasis , asymptomatic , requirement steroid antiseizure medication one week prior first dose study drug . Clinically significant gastrointestinal abnormality . Presence uncontrolled infection . Corrected QT interval great 480 msec . History significant cardiovascular condition ( ) . Poorly control hypertension ( systolic blood pressure 140mmHG great diastolic blood pressure 90mmHg great ) . History cerebrovascular accident , pulmonary embolism , insufficiently treat deep venous thrombosis within past 6 month prior first dose study drug . Major surgery trauma within 28 day prior first dose study drug and/or presence nonhealing wound , fracture , ulcer . Active bleeding diathesis . Hemoptysis excess 2.5mL within 8 week first dose study drug . Serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure . Use prohibit medication define protocol . Use investigational agent , include investigational anticancer agent within 28 day , 5 halflives , whichever longer , prior first dose study drug . Prior use investigational license antiangiogenic agent , include thalidomide agent target plateletderived growth factor . Prior treatment bevacizumab epidermal growth factor receptor tyrosine kinase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>anti-angiogenesis</keyword>
	<keyword>Non-small cell lung cancer ,</keyword>
	<keyword>pazopanib ( GW786034 )</keyword>
</DOC>